Table 2 |
|||||
|
In vitro parameters of GC sensitivity and relative decrease in DAS |
|||||
|
Bioassays |
GC binding assay |
||||
|
|
|
||||
|
β (95% CI)a |
P value |
β (95% CI)a |
P value |
||
|
|
|
||||
|
IL-2-EC50 |
-0.014 (-0.028-0.001) |
0.058 |
KD |
0.03 (0.014-0.046) |
0.001 |
|
|
|
||||
|
Age |
0.005 (-0.002-0.110) |
0.161 |
Age |
0.009 (0.002-0.017) |
0.020 |
|
Gender |
0.128 (-0.057-0.312) |
0.169 |
Gender |
0.199 (0.013-0.385) |
0.037 |
|
Use of NSAID |
0.087 (-0.087-0.261) |
0.316 |
Use of NSAID |
0.212 (0.025-0.400) |
0.028 |
|
Number of DMARDs |
0.023 (-0.079-0.125) |
0.647 |
Number of DMARDs |
0.112 (0.004-0.221) |
0.043 |
|
Use of anti-TNF-α |
0.008 (-0.283-0.299) |
0.955 |
Use of anti-TNF-α |
0.222 (-0.010-0.455) |
0.060 |
|
|
|
||||
|
GILZ-EC50 |
-0.023 (-0.046-0.001) |
0.062 |
GR number/1,000 |
0.027 (0.012-0.042) |
0.001 |
|
|
|
||||
|
Age |
0.006 (-0.001-0.014) |
0.079 |
Age |
0.010 (0.002-0.018) |
0.015 |
|
Gender |
0.116 (-0.075-0.308) |
0.225 |
Gender |
0.017 (-0.188-0.223) |
0.862 |
|
Use of NSAID |
0.181 (-0.004-0.366) |
0.055 |
Use of NSAID |
0.203 (0.006-0.400) |
0.044 |
|
Number of DMARDs |
0.021 (-0.085-0.126) |
0.695 |
Number of DMARDs |
0.084 (-0.027-0.195) |
0.132 |
|
Use of anti-TNF-α |
0.023 (-0.270-0.320) |
0.874 |
Use of anti-TNF-α |
0.129 (-0.121-0.378) |
0.297 |
|
|
|||||
|
In all four models, relative decrease in DAS was the dependent variable. The data represent the combined bioassays from intramuscularly treated patients with early (n = 14) and established RA (n = 31). GILZ-EC50 and IL-2-EC50 were not associated with relative decrease in DAS in orally treated patients in recent-onset RA (n = 22). The GC-binding assay is performed only in established RA (n = 30, all intramuscular GC). aValues represent adjusted β-coefficients and 95% confidence intervals. |
|||||
|
Quax et al. Arthritis Research & Therapy 2012 14:R195 doi:10.1186/ar4029 |
|||||
